Characterization of safety of inpatient care in surgical settings
1. Adverse events were identified in more than one third of patients admitted to hospital for surgery, nearly half of ...
Tag: internal medicine
Pomalidomide effective in reducing epistaxis in hereditary hemorrhagic telangiectasia
1. Among patients with hereditary hemorrhagic telangiectasia (HHT), pomalidomide significantly reduced the severity of epistaxis and improved quality of life. ...
Ziresovir reduces the severity of respiratory syncytial virus in hospitalized infants
1. Ziresovir, an antiviral drug targeted at respiratory syncytial virus (RSV), was superior to placebo in reducing signs and symptoms ...
Fidanacogene elaparovovec may reduce bleeding in men with hemophilia B
1. In this randomized controlled trial, fidanacogene elaparovovec therapy significantly reduced the mean annualized rate of bleeding in adult men ...
Axatilimab reduces symptoms in patients with graft versus host disease
1. In this randomized controlled trial, axatilimab effectively managed symptoms in patients with recurrent or refractory graft versus host disease ...
Tulisokibart effectively induces clinical remission in moderately to severely active ulcerative colitis
1. In this randomized controlled trial, among patients with moderately to severely active ulcerative colitis, tulisokibart, a monoclonal antibody directed ...
Intravenous amino acids decrease acute kidney injury following cardiac surgery
1. In this randomized controlled trial, in patients undergoing cardiopulmonary bypass, continuous intravenous (IV) administration of amino acids was found ...
Risankizumab is superior to ustekinumab for endoscopic remission of Crohn’s disease
1. In this randomized controlled trial, risankizumab was non-inferior to ustekinumab in terms of clinical remission at 24 weeks in ...
Efanesoctocog alfa in children with hemophilia A reduces bleeding
1. In this randomized controlled trial, a prophylactic weekly dose of efanesoctocog alfa (ALTUVIIIO) resulted in sustained factor VIII activity ...
Benralizumab associated with histologic response in eosinophilic esophagitis
1. In this randomized controlled trial, benralizumab, an anti-interleukin-5 receptor (anti-IL-5R) monoclonal antibody, demonstrated histologic depletion of eosinophils among patients ...
